AIM 7: THE PREVENTION OF NOCTURNAL HYPOGLYCEMIA IN TYPE 1 DIABETES

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。医源性低血糖，尤其是夜间低血糖，是糖尿病血糖控制的限制因素（Cryer et al ., diabetes Care 26:1902, 2003）。以夜间最低血糖浓度为主要终点，我们计划对比三种已报道有效的睡前治疗——特布他林、玉米淀粉、阿卡波糖——与标准治疗、常规睡前零食和不治疗的1型糖尿病患者，这些患者的糖尿病管理非常积极，HbA1c <=8.0%，早晨自我监测血糖值<=120mg/dL。患者将在5个GCRC过夜期间接受随机顺序的睡前治疗。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Iatrogenic hypoglycemia, particularly nocturnal hypoglycemia, is the limiting factor in the glycemic management of diabetes (Cryer et al, Diabetes Care 26:1902, 2003). Using the nocturnal nadir plasma glucose concentration as the primary endpoint, we plan to contrast three bedtime treatments that have been reported to be effective - terbutaline, cornstarch, acarbose - with the standard treatment, a conventional bedtime snack, and no treatment in patients with type 1 diabetes who are managing their diabetes aggressively as evidenced by a HbA1c of <=8.0% and a goal of morning self-monitoring of blood glucose values <=120mg/dL. Patients will be sampled during five overnight GCRC stays with the bedtime treatments given in random sequence.